| Size | Price | Stock | Qty |
|---|---|---|---|
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
|
| ln Vitro |
Human osteoarthritis nurse cells have no effect on the viability of saikosaponin A (5–15 μM, 24 hours) [1]. Saikosaponin A (5-15 μM, 24 h) increases the expression of LXRα in a dose-dependent manner and suppresses the generation of NO, PGE2, and NF-κB produced by IL-1β [1].
|
|---|---|
| ln Vivo |
Saikosaponin A (1-10 mg/kg, intraperitoneal injection, 7 days) can stop the morphological alterations brought on by 5-FU in the small intestine. [2]. Saikosaponin-A (1–10 mg/kg, intraperitoneal, 7 days) improves 5-FU-induced mucositis in 5
|
| Cell Assay |
Western Blot Analysis
Cell Types: Human Osteoarthritis Chondrocytes Tested Concentrations: 5, 10, 15 μM Incubation Duration: 24. h Experimental Results: Inhibition of IL-1β-induced NF-κB p65 and IκBα phosphorylation levels. Upregulates the expression of LXRα in a dose-dependent manner. |
| Animal Protocol |
Animal/Disease Models: BALB/c mouse model [2]
Doses: 1, 5, 10 mg /kg/day, 7 d Route of Administration: intraperitoneal (ip) injection Experimental Results: diminished villous blunting, crypt cell apoptosis and inflammatory cell infiltration. The concentrations of GSH, GST, catalase and SOD in intestinal tissue were diminished. |
| References | |
| Additional Infomation |
Saikosaponin A is a saikosaponin.
Saikosaponin A has been reported in Bupleurum chinense, Scrophularia kakudensis, and other organisms with data available. |
| Molecular Formula |
C42H68O13
|
|---|---|
| Molecular Weight |
780.99
|
| Exact Mass |
780.466
|
| CAS # |
20736-09-8
|
| Related CAS # |
20736-09-8;
|
| PubChem CID |
167928
|
| Appearance |
White to off-white solid powder
|
| Density |
1.4±0.1 g/cm3
|
| Boiling Point |
893.7±65.0 °C at 760 mmHg
|
| Melting Point |
225 - 235ºC
|
| Flash Point |
494.3±34.3 °C
|
| Vapour Pressure |
0.0±0.6 mmHg at 25°C
|
| Index of Refraction |
1.617
|
| LogP |
3.65
|
| Hydrogen Bond Donor Count |
8
|
| Hydrogen Bond Acceptor Count |
13
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
55
|
| Complexity |
1490
|
| Defined Atom Stereocenter Count |
21
|
| SMILES |
C[C@@H]1[C@@H]([C@@H]([C@H]([C@@H](O1)O[C@H]2CC[C@]3([C@H]([C@]2(C)CO)CC[C@@]4([C@@H]3C=C[C@@]56[C@]4(C[C@@H]([C@@]7([C@H]5CC(CC7)(C)C)CO6)O)C)C)C)O)O[C@H]8[C@@H]([C@H]([C@@H]([C@H](O8)CO)O)O)O)O
|
| InChi Key |
KYWSCMDFVARMPN-MSSMMRRTSA-N
|
| InChi Code |
InChI=1S/C42H68O13/c1-21-28(46)33(55-34-31(49)30(48)29(47)22(18-43)53-34)32(50)35(52-21)54-27-10-11-37(4)23(38(27,5)19-44)8-12-39(6)24(37)9-13-42-25-16-36(2,3)14-15-41(25,20-51-42)26(45)17-40(39,42)7/h9,13,21-35,43-50H,8,10-12,14-20H2,1-7H3/t21-,22-,23-,24-,25-,26+,27+,28+,29-,30+,31-,32-,33+,34+,35+,37+,38+,39-,40+,41-,42+/m1/s1
|
| Chemical Name |
(2S,3R,4S,5S,6R)-2-[(2R,3R,4S,5S,6R)-3,5-dihydroxy-2-[[(1S,2S,4S,5R,8R,9R,10S,13S,14R,17S,18R)-2-hydroxy-9-(hydroxymethyl)-4,5,9,13,20,20-hexamethyl-24-oxahexacyclo[15.5.2.01,18.04,17.05,14.08,13]tetracos-15-en-10-yl]oxy]-6-methyloxan-4-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~128.04 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (3.20 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (3.20 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (3.20 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.2804 mL | 6.4021 mL | 12.8043 mL | |
| 5 mM | 0.2561 mL | 1.2804 mL | 2.5609 mL | |
| 10 mM | 0.1280 mL | 0.6402 mL | 1.2804 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
